Skip to main content
SpringerLink
Log in

Calcitonin gene-related peptide-targeted therapies are effective options for the prevention and treatment of migraine

  • Practical Issues and Updates
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Calcitonin gene-related peptide (CGRP)-targeted therapies have established efficacy in the treatment of migraine and are generally well tolerated. CGRP-targeted monoclonal antibodies are effective for the prevention of migraine, with convenient dosage regimens. Injection site reactions are the most common adverse events with CGRP-targeted monoclonal antibodies. Small molecule CGRP receptor antagonists (gepants) are effective options for the prevention or acute treatment of migraine and most have similar rates of adverse events to placebo. Combination preventative therapy could be considered if the response to single preventative therapy is inadequate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ferrari MD, Goadsby PJ, Burstein R, et al. Migraine. Nat Rev Dis Primers. 2022;8(1):2.

    PubMed  Google Scholar 

  2. Yuan H, Lauritsen CG, Kaiser EA, et al. CGRP monoclonal antibodies for migraine: rationale and progress. BioDrugs. 2017;31(6):487–501.

    CAS  PubMed  Google Scholar 

  3. Cohen F, Yuan H, Silberstein SD. Calcitonin gene-related peptide (CGRP)-targeted monoclonal antibodies and antagonists in migraine: current evidence and rationale. BioDrugs. 2022;36(3):341–58.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021–39.

    PubMed  Google Scholar 

  5. Sacco S, Amin FM, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention—2022 update. J Headache Pain. 2022;23(1):67.

    PubMed  PubMed Central  Google Scholar 

  6. Forbes RB, McCarron M, Cardwell CR. Efficacy and contextual (placebo) effects of CGRP antibodies for migraine: systematic review and meta-analysis. Headache. 2020;60(8):1542–57.

    PubMed  Google Scholar 

  7. Reuter U, Ehrlich M, Gendolla A, et al. Erenumab versus topiramate for the prevention of migraine—a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia. 2021;42(2):108–18.

    PubMed  PubMed Central  Google Scholar 

  8. Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123–32.

    CAS  PubMed  Google Scholar 

  9. Dodick DW, Ashina M, Brandes JL, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026–37.

    PubMed  Google Scholar 

  10. Wang SJ, Roxas AA Jr, Saravia B, et al. Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: the EMPOwER study. Cephalalgia. 2021;41(13):1285–97.

    PubMed  PubMed Central  Google Scholar 

  11. Goadsby PJ, Reuter U, Hallström Y, et al. One-year sustained efficacy of erenumab in episodic migraine: results of the STRIVE study. Neurology. 2020;95(5):e469–79.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392(10161):2280–7.

    CAS  PubMed  Google Scholar 

  13. Goadsby PJ, Reuter U, Lanteri-Minet M, et al. Long-term efficacy and safety of erenumab: results from 64 weeks of the LIBERTY study. Neurology. 2021;96(22):e2724–35.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Takeshima T, Sakai F, Hirata K, et al. Erenumab treatment for migraine prevention in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. Headache. 2021;61(6):927–35.

    PubMed  PubMed Central  Google Scholar 

  15. Lattanzi S, Brigo F, Trinka E, et al. Erenumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety. Drugs. 2019;79(4):417–31.

    CAS  PubMed  Google Scholar 

  16. Do TP, Younis S, Ashina M. Erenumab. In: van den Brink AM, Martelletti P, editors. Monoclonal antibodies in headache. Cham: Springer; 2021. p. 121–9.

    Google Scholar 

  17. Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080–8.

    PubMed  PubMed Central  Google Scholar 

  18. Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442–54.

    PubMed  Google Scholar 

  19. Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Detke H, Pozo-Rosich P, Reuter U, et al. One-year treatment with Galcanezumab in patients with chronic migraine: results from the open-label phase of the REGAIN study [abstract no. P2.10-010]. Neurology. 2019;92(Suppl 15).

  21. Mulleners WM, Kim B-K, Lainez MJ, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19(10):814–25.

    CAS  PubMed  Google Scholar 

  22. Reuter U, Lucas C, Dolezil D, et al. Galcanezumab in patients with multiple previous migraine preventive medication category failures: results from the open-label period of the CONQUER trial. Adv Ther. 2021;38(11):5465–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Gklinos P, Mitsikostas DD. Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials. Ther Adv Neurol Disord. 2020;13:1756286420918088.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113–22.

    CAS  PubMed  Google Scholar 

  25. Sakai F, Suzuki N, Kim B-K, et al. Efficacy and safety of fremanezumab for chronic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache. 2021;61(7):1092–101.

    PubMed  PubMed Central  Google Scholar 

  26. Goadsby PJ, Silberstein SD, Yeung PP, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology. 2020;95(18):e2487–99.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319(19):1999–2008.

    CAS  PubMed  Google Scholar 

  28. Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394(10203):1030–40.

    CAS  PubMed  Google Scholar 

  29. Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241–54.

    PubMed  PubMed Central  Google Scholar 

  30. Smith TR, Janelidze M, Chakhava G, et al. Eptinezumab for the prevention of episodic migraine: sustained effect through 1 year of treatment in the PROMISE-1 study. Clin Ther. 2020;42(12):2254-65.e3.

    CAS  PubMed  Google Scholar 

  31. Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94(13):e1365–77.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Silberstein S, Diamond M, Hindiyeh NA, et al. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (prevention of migraine via intravenous ALD403 safety and efficacy-2) study. J Headache Pain. 2020;21(1):120.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Pzifer Inc. Zavzpret (zavegepant) nasal spray: US prescribing information. 2023. https://www.accessdata.fda.gov/. Accessed 19 Apr 2023.

  34. Lipton RB, Croop R, Stock DA, et al. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol. 2023;22(3):209–17.

    CAS  PubMed  Google Scholar 

  35. Hutchinson S, Dodick DW, Treppendahl C, et al. Ubrogepant for the acute treatment of migraine: pooled efficacy, safety, and tolerability from the ACHIEVE I and ACHIEVE II phase 3 randomized trials. Neurol Ther. 2021;10(1):235–49.

    PubMed  PubMed Central  Google Scholar 

  36. Gao B, Yang Y, Wang Z, et al. Efficacy and safety of rimegepant for the acute treatment of migraine: evidence from randomized controlled trials. Front Pharmacol. 2019;10:1577.

    CAS  PubMed  Google Scholar 

  37. Croop R, Madonia J, Stock DA, et al. Zavegepant nasal spray for the acute treatment of migraine: a phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial. Headache. 2022;62(9):1153–63.

    PubMed  PubMed Central  Google Scholar 

  38. Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385(8):695–706.

    CAS  PubMed  Google Scholar 

  39. Goadsby PJ, Dodick DW, Ailani J, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol. 2020;19(9):727–37.

    CAS  PubMed  Google Scholar 

  40. Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230–41.

    CAS  PubMed  Google Scholar 

  41. Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs. placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887–98.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142–9.

    CAS  PubMed  Google Scholar 

  43. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737–45.

    CAS  PubMed  Google Scholar 

  44. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51–60.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand

    Tina Nie

Authors
  1. Tina Nie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tina Nie.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and conflict of interest

T. Nie is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability

Not applicable.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nie, T. Calcitonin gene-related peptide-targeted therapies are effective options for the prevention and treatment of migraine. Drugs Ther Perspect 39, 195–199 (2023). https://doi.org/10.1007/s40267-023-00995-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-023-00995-1

Search

Navigation